Australia's most trusted
source of pharma news
Saturday, 19 July 2025
Posted 18 July 2025 AM
Boehringer Ingelheim has decided to offload global rights for Spevigo to Danish dermatology leader Leo Pharma, which will pay US$105 million upfront for the psoriasis treatment.
While the full terms of the deal were not disclosed as both companies are privately owned, LEO confirmed that it is in line for milestone payments and royalties. The deal is expected to close in the second half of 2025.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.